Biotech Implosion: Allos Therapeutics

by Jon C. Ogg
24/7 Wall St.



Allos Therapeutics, Inc. (ALTH) is indicated down almost 20% in thin pre-market trading after it announced that top line results from ENRICH, the Company's pivotal Phase III study of EFAPROXYN plus whole brain radiation therapy (WBRT) in women with brain metastases originating from breast cancer. The study failed to achieve its primary endpoint of demonstrating a statistically significant improvement in overall survival in patients receiving EFAPROXYN plus WBRT, compared to patients receiving WBRT alone. All secondary efficacy endpoints also failed to achieve statistical significance.

Based on these results, Allos intends to discontinue the development of EFAPROXYN and focus on advancing the development of PDX (Pralatrexate), its novel antifolate currently under evaluation in a pivotal Phase 2 study in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).


Continue article at 247WallSt.com



RELATED READING:
- Atherogenics Implodes as Heart Disease Study Fails
- Allos Therapeutics Announces $50.5M Financing Deal



247WallSt.com is a regular contributor to BioHealthInvestor.com
_______________